Seeking Alpha

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...
Business Wire

Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...
SUNY-ESF

Bachelor of Science in Biotechnology

Biotechnology is the application of biological organisms, cells, or molecules to produce a product or service for the betterment of humankind. This area of study includes aspects of molecular biology, ...
Nasdaq

Sana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 Diabetes

Sana Biotechnology reports six-month results from a first-in-human study demonstrating safe pancreatic islet cell transplantation for type 1 diabetes without immunosuppression. Sana Biotechnology ...
Nasdaq

UNITY Biotechnology to Present 36-Week Data from ASPIRE Phase 2B Study at ARVO 2025 Annual Meeting

UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...
Seeking Alpha

Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...